Trial Profile
A retrospective study to evaluate the efficacy and safety of Brentuximab-vedotin in patients with Hodgkin's lymphoma progressing or relapsing after allogeneic stem cell transplantation.
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 28 Nov 2015 New trial record